-
Je něco špatně v tomto záznamu ?
Vitamin B6 modifies the immune cross-talk between mononuclear and colon carcinoma cells
H. Bessler, M. Djaldetti
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
ProQuest Central
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
- MeSH
- antiflogistika metabolismus MeSH
- cytokiny sekrece MeSH
- dospělí MeSH
- interferon gama sekrece MeSH
- leukocyty mononukleární účinky léků imunologie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- nádory tračníku imunologie patologie MeSH
- viabilita buněk účinky léků MeSH
- vitamin B6 farmakologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The role of vitamin B6 as a key component in a number of biological events has been well established. Based on the relationship between chronic inflammation and carcinogenesis on the one hand, and the interaction between immune and cancer cells expressed by modulated cytokine production on the other hand, the aim of the present work was to examine the possibility that vitamin B6 affects cancer development by an interference in the cross-talk between human peripheral blood mononuclear cells (PBMC) and those from two colon carcinoma cell lines. Both non-stimulated PBMC and mononuclear cells induced for cytokine production by HT-29 and RKO cells from human colon carcinoma lines were incubated without and with 4, 20 and 100 μg/ml of pyridoxal hydrochloride (vitamin B6) and secretion of TNF-α, IL-1β, IL-6, IFN-γ, IL-10, and IL-1ra was examined. Vit B6 caused a dose-dependent decrease in production of all cytokines examined, except for that of IL-1ra. The results indicate that vitamin B6 exerts an immunomodulatory effect on human PBMC. The finding that production of inflammatory cytokines is more pronounced when PBMC are in contact with malignant cells and markedly inhibited by the vitamin suggests an additional way by which vitamin B6 may exert its carcinopreventive effect.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17004359
- 003
- CZ-PrNML
- 005
- 20170223072515.0
- 007
- ta
- 008
- 170127s2016 xr f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)27085010
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Bessler, H. $u Laboratory for Immunology and Hematology Research, Rabin Medical Center, Hasharon Hospital, Petah Tiqva, and the Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel
- 245 10
- $a Vitamin B6 modifies the immune cross-talk between mononuclear and colon carcinoma cells / $c H. Bessler, M. Djaldetti
- 520 9_
- $a The role of vitamin B6 as a key component in a number of biological events has been well established. Based on the relationship between chronic inflammation and carcinogenesis on the one hand, and the interaction between immune and cancer cells expressed by modulated cytokine production on the other hand, the aim of the present work was to examine the possibility that vitamin B6 affects cancer development by an interference in the cross-talk between human peripheral blood mononuclear cells (PBMC) and those from two colon carcinoma cell lines. Both non-stimulated PBMC and mononuclear cells induced for cytokine production by HT-29 and RKO cells from human colon carcinoma lines were incubated without and with 4, 20 and 100 μg/ml of pyridoxal hydrochloride (vitamin B6) and secretion of TNF-α, IL-1β, IL-6, IFN-γ, IL-10, and IL-1ra was examined. Vit B6 caused a dose-dependent decrease in production of all cytokines examined, except for that of IL-1ra. The results indicate that vitamin B6 exerts an immunomodulatory effect on human PBMC. The finding that production of inflammatory cytokines is more pronounced when PBMC are in contact with malignant cells and markedly inhibited by the vitamin suggests an additional way by which vitamin B6 may exert its carcinopreventive effect.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antiflogistika $x metabolismus $7 D000893
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a nádory tračníku $x imunologie $x patologie $7 D003110
- 650 _2
- $a cytokiny $x sekrece $7 D016207
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interferon gama $x sekrece $7 D007371
- 650 _2
- $a leukocyty mononukleární $x účinky léků $x imunologie $7 D007963
- 650 _2
- $a vitamin B6 $x farmakologie $7 D025101
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Djaldetti, M. $u Laboratory for Immunology and Hematology Research, Rabin Medical Center, Hasharon Hospital, Petah Tiqva, and the Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel
- 773 0_
- $w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 62, č. 1 (2016), s. 47-52
- 856 41
- $u http://fb.cuni.cz/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 970 $c 89 $y 4 $z 0
- 990 __
- $a 20170127 $b ABA008
- 991 __
- $a 20170220142230 $b ABA008
- 999 __
- $a ok $b bmc $g 1190094 $s 964975
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 62 $c 1 $d 47-52 $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
- LZP __
- $b NLK118 $a Pubmed-20170127